The MHRA states that these medicines are licensed to treat specific medical disorders and should not be used if you are not overweight or diabetic or want to lose weight for aesthetic or cosmetic purposes
the Feeding and Eating Disorders category includes three disorders as manifested by persistent failure to meet appropriate nutritional and/or energy needs and significant weight loss, AN, avoidant/restrictive food intake disorder (ARFIDO), and atypical AN
Step 5: Label and Refrigerate Write the reconstitution date on the vial
Building on the understanding that GLP-1 agonists induce weight loss through appetite suppression and slowed gastric emptying, it is crucial to recognize the potential downstream consequences of these mechanisms, particularly regarding nutritional status
Register here today: Are you using a GLP-1 medication or curious about their day-to-day impact
If your body's telling you something is changing, and you cannot explain it in any way, have this discussion with your primary care physician. Jin A et al
